Woodline Partners LP Raises Stock Position in Replimune Group, Inc. (NASDAQ:REPL)

Woodline Partners LP lifted its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 156.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 854,309 shares of the company's stock after buying an additional 521,366 shares during the period. Woodline Partners LP owned about 1.25% of Replimune Group worth $10,346,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Velan Capital Investment Management LP bought a new position in shares of Replimune Group in the fourth quarter worth approximately $2,196,000. Soleus Capital Management L.P. bought a new position in Replimune Group during the fourth quarter valued at approximately $3,179,000. Two Sigma Investments LP lifted its position in Replimune Group by 18.6% during the fourth quarter. Two Sigma Investments LP now owns 212,586 shares of the company's stock valued at $2,574,000 after purchasing an additional 33,346 shares during the period. Tang Capital Management LLC lifted its position in Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock valued at $32,697,000 after purchasing an additional 1,500,000 shares during the period. Finally, RTW Investments LP lifted its position in Replimune Group by 82.1% during the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after purchasing an additional 931,223 shares during the period. Institutional investors own 92.53% of the company's stock.

Insider Transactions at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 25,105 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $202,346.30. Following the completion of the transaction, the chief executive officer now directly owns 343,576 shares of the company's stock, valued at $2,769,222.56. This trade represents a 6.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Andrew Schwendenman sold 3,287 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $26,460.35. Following the completion of the transaction, the chief accounting officer now directly owns 68,284 shares of the company's stock, valued at $549,686.20. The trade was a 4.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock valued at $603,655 over the last three months. Corporate insiders own 8.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $19.43.

Replimune Group Stock Performance

REPL stock traded up $0.32 during midday trading on Wednesday, reaching $8.74. 306,990 shares of the company's stock traded hands, compared to its average volume of 926,200. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The stock has a market cap of $673.11 million, a P/E ratio of -2.85 and a beta of 0.68. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock's 50-day moving average is $8.50 and its 200 day moving average is $11.15.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the firm earned ($0.25) EPS. As a group, analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.